Patents by Inventor Archie C. Swindell

Archie C. Swindell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hydroxylated metabolites and derivatives of doxazosin as anti-atherosclerosis agents
    Patent number: 5543411
    Abstract: This invention relates to the use of certain hydroxylated metabolites and derivatives of doxazosin and their pharmaceutically acceptable acid addition salts for retarding the development of atherosclerosis in a mammal. Such compounds are useful for reducing atherosclerotic plaque involvement and for retarding and reducing both lipid deposition fibrosis in the development of atherosclerotic plaques.
    Type: Grant
    Filed: May 8, 1995
    Date of Patent: August 6, 1996
    Assignee: Pfizer Inc.
    Inventors: Archie C. Swindell, Samuel S. Wong
  • dl-5-[(2-benzyl-3,4-dihydro-2H-benzopyran-6-yl)m ethyl]thiazolidine-2,4-dione as an anti-atherosclerosis agent
    Patent number: 4798835
    Abstract: This invention relates of the use of a certain thiazolidine-2,4-dione, namely, dl-5-[(2-benzyl-3,4-dihydro-2H-benzopyran-6-yl)methyl]thiazolidine-2,4-dio ne, or a pharmaceutically acceptable cationic salt thereof, for retarding the development of arterial disease in mammals. More specifically, it relates to a method for reducing the serum cholesterol levels in mammals by administering to said mammals dl-5-[(2-benzyl-3,4-dihydro-2H-benzopyran-6-yl)methyl]-thiazolidine-2,4-di one or a pharmaceutically acceptable cationic salt thereof.
    Type: Grant
    Filed: December 2, 1987
    Date of Patent: January 17, 1989
    Assignee: Pfizer Inc.
    Inventors: Michael N. Krupp, Archie C. Swindell
  • Doxazosin as an anti-atherosclerosis agent
    Patent number: 4758569
    Abstract: This invention relates to the use of doxazosin or a pharmaceutically acceptable acid addition salt thereof as an agent for retarding the development of atherosclerosis in a mammal, especially for reducing atherosclerotic plaque involvement and for retarding and reducing both the fibrosis and lipid deposition of developing atherosclerotic plaques associated with atherosclerosis.
    Type: Grant
    Filed: August 26, 1987
    Date of Patent: July 19, 1988
    Assignee: Pfizer Inc.
    Inventor: Archie C. Swindell
  • Trimazosin as an anti-atherosclerosis agent
    Patent number: 4582832
    Abstract: The use of trimazosin or a pharmaceutically acceptable acid addition salt thereof as an agent for retarding the development of atherosclerosis in a mammal, especially for retarding and reducing the development of fibrous plaques associated with atherosclerosis.
    Type: Grant
    Filed: August 28, 1985
    Date of Patent: April 15, 1986
    Assignee: Pfizer Inc.
    Inventor: Archie C. Swindell